Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone267-440-4200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.22 million
Profitability
Miscellaneous
Employees280
OptionableOptionable
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Shares of Inovio Pharmaceuticals reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) released its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.05. The biopharmaceutical company had revenue of $2 million for the quarter, compared to analysts' expectations of $2.20 million. Inovio Pharmaceuticals had a negative return on equity of 72.66% and a negative net margin of 232.58%. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. View Inovio Pharmaceuticals' Earnings History.
When is Inovio Pharmaceuticals' next earnings date?
What price target have analysts set for INO?
4 brokers have issued 12 month price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $10.75 in the next twelve months. This suggests a possible upside of 111.6% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.
What is the consensus analysts' recommendation for Inovio Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Regeneron and AstraZeneca, which helps the company with the their derived expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio andits excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares of the company have outperformed the industry in 2018. Loss estimates looks stable ahead of the Q4 earnings release. Inovio has a positive record of earnings surprises in recent quarters." (1/16/2019)
- 2. Maxim Group analysts commented, "Inovio announced the publication of a preclinical study highlighting the successful development of optimized DNA-encoded monoclonal antibodies (dMABs) targeting the immune checkpoint PD-1." (1/15/2019)
- 3. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $1.4B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate and 80% probability of success." (12/5/2018)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
News coverage about INO stock has trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), K2M Group (KTWO), AtriCure (ATRC), Luminex (LMNX), Tactile Systems Technology (TCMD), Cryolife (CRY), Cardiovascular Systems (CSII), Orthofix Medical (OFIX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR) and SurModics (SRDX).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
- Mr. Peter D. Kies, Chief Financial Officer (Age 56)
- Dr. Niranjan Y. Sardesai, Chief Operating Officer (Age 51)
- Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
- Dr. Laurent M. Humeau, Sr. VP of R&D and Chief Scientific Officer
Who are Inovio Pharmaceuticals' major shareholders?
Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.03%), Meeder Asset Management Inc. (0.02%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Which major investors are buying Inovio Pharmaceuticals stock?
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $5.08.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $468.15 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.
What is Inovio Pharmaceuticals' official website?
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
